#Diagnostics #Health / Well-being
- Sickle cell disease
- Red blood cell
- Predictive algorithm
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.Discover >
Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
#Diagnostics #Health / Well-being
Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease
INNOVHEM was created in October 2019 to join the Genopole Booster program.
With our expertise, we are developing the measurement of new bio-markers, which, in combination with artificial intelligence, will allow to assess the severity of the disease and to predict it.
From 2020, INNOVHEM proposes to perform bioassays to measure fetal hemoglobin and intravascular hemolysis (the degradation of red blood cells), as a service for pharmaceutical companies.
These biomarkers are used to evaluate the efficacy of treatments under development. In parallel, INNOVHEM develops tools that combine the measurement of these biomarkers with AI to allow clinicians to improve patient management.
INNOVHEM has signed a contract that provides the exclusive and worldwide exploitation of 3 patents that cover the two innovations originating from academic research (measurement of HbF by red blood cell and intra-vascular hemolysis).
INNOVHEM has also set up collaborations with institutions (Inserm, APHP, UPEC and EFS) for the research and development of these innovations. At the end of November 2020, INNOVHEM signed a first contract for a research study, funded by a private company.
Finally, in mid-December 2020, INNOVHEM recruited its first project manager.
– Strong partnership with academic research
– Close relations with industrials
In same field
CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.Discover
Research & development for an in vitro diagnostic tool for endometriosisDiscover
SafeInsight seeks to provide a response to the growing concerns of consumers for the composition of the products they buy and accompanies manufacturers aiming to attentively circumscribe the problem of endocrine disruptors.Discover
Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.Discover
Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.Discover
Floating Genes develops diagnostic tools for use in liquid biopsies via the highly sensitive NGS detection of circulating tumor DNA.Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.Discover
IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.Discover
Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.Discover
AgenT is developing an unprecedented blood test to identify patients with Alzheimer's disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer's disease.Discover